Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01663740 · ClinicalTrials.gov registry record · Phase 4
A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls
A Phase 4 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 4
- Development phase
- 59
- Enrollment target
NCT01663740 is a Phase 4 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 59 participants.
The verdict
NCT01663740, a Phase 4 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 59 participants
- Enrollment target
Study Summary
This observational study will compare spermatogenesis in male adult renal transplant recipients receiving valganciclovir versus untreated matched controls. Data will be collected from each participant for up to 52 weeks post transplant.
Interventions
- DRUG Valganciclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2012-01-30 |
| Est. Completion | 2016-12-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01663740
The ClinicalTrials.gov registry entry for NCT01663740 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Valganciclovir is the first listed.
NCT01663740 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01663740 about?
NCT01663740 is a clinical study titled "A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls". This observational study will compare spermatogenesis in male adult renal transplant recipients receiving valganciclovir versus untreated matched controls. Data will be collected from each participant for up to 52 weeks post transplant.
What is the current status of trial NCT01663740?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 59 participants. The study started on 2012-01-30. Estimated completion is 2016-12-30.
What interventions are being tested in trial NCT01663740?
The interventions under investigation include: Valganciclovir (DRUG).
Who is sponsoring clinical trial NCT01663740?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.